Circulating tumor DNA (ctDNA) refers to free tumor DNA fragments located in peripheral circulation. These free nucleic acids not only provide a comprehensive view of tumor genetics but also indirectly reflect tumor progression, heterogeneity, and invasive ability. They represent a promising non-invasive biomarker in cancer treatment. Dr. Claudia Campani from the University of Paris delivered an oral presentation at the 17th International Liver Cancer Association Annual Meeting (ILCA 2023) (Abstract No.: O-04). The study aimed to assess the dynamic changes in ctDNA levels in hepatocellular carcinoma (HCC) patients across different tumor stages and during anti-cancer treatments. The findings highlighted the significant clinical relevance of monitoring ctDNA levels for HCC patients. Dr. Claudia Campani was honored with the "Young Investigator" award by the ILCA conference.
